Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Edward C, Keystone"'
Autor:
Viviane Ta, Orit Schieir, Marie‐France Valois, Ines Colmegna, Carol Hitchon, Louis Bessette, Glen Hazlewood, Carter Thorne, Janet Pope, Gilles Boire, Diane Tin, Edward C. Keystone, Vivian P. Bykerk, Susan J. Bartlett
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 7, Pp 566-573 (2022)
Objective Adults with rheumatoid arthritis (RA) are at a higher risk for infections, including influenza and related complications. We identified influenza vaccination coverage in adults newly diagnosed with RA and examined sociodemographic RA charac
Externí odkaz:
https://doaj.org/article/d61efb87226145f788a7dc82f6d960df
Autor:
Mohammad Movahedi, Angela Cesta, Claire Bombardier, Edward C Keystone, Denis Choquette, Xiuying Li, Louis Coupal, OBRI Investigators
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Objectives The similarity in retention of tumour necrosis factor inhibitors (TNFi) and tofacitinib (TOFA) was previously reported separately by the Ontario Best Practices Research Initiative and the Quebec cohort Rhumadata. However, because of small
Externí odkaz:
https://doaj.org/article/8f53dc2c72664f579fc929d264b61f25
Autor:
Kathleen M. Andersen, Orit Schieir, Marie‐France Valois, Susan J. Bartlett, Louis Bessette, Gilles Boire, Boulos Haraoui, Glen Hazlewood, Carol Hitchon, Edward C. Keystone, Janet Pope, Diane Tin, J Carter Throne, Vivian P. Bykerk, CATCH Investigators
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 1, Pp 57-64 (2022)
Objective To describe patterns of glucocorticoid use in a large real‐world cohort with early rheumatoid arthritis (RA) and assess the impact on disease activity and treatment. Methods Data are from adults with new RA (≤1 year) recruited to the Ca
Externí odkaz:
https://doaj.org/article/28cce0e812f14d11b8daa54659bd07b0
Autor:
Josef S. Smolen, Young Mo Kang, Wan-Hee Yoo, Paul Emery, Michael E. Weinblatt, Edward C. Keystone, Mark C. Genovese, Gihyun Myung, Inyoung Baek, Jeehoon Ghil
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-9 (2020)
Abstract Objective Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA).
Externí odkaz:
https://doaj.org/article/078e3fc0c86e4ce59dfa6b3cf0caed92
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 3, Pp 188-194 (2020)
Objective Progressive rheumatoid arthritis (RA) is responsible for joint damage causing disabilities, but there is no agreement on which disease measures best predict radiographic progression. We aimed to determine which disease activity measures, in
Externí odkaz:
https://doaj.org/article/1c88ed38c23e48db9fbf01018d132cae
Autor:
Boulos Haraoui, Janet Pope, Edward C Keystone, Eduardo Mysler, Tatjana Lukic, Harry Shi, Stanley B Cohen, Rebecca Germino, Lori Stockert, Annette Diehl, Sujatha Menon, Shixue Liu
Publikováno v:
RMD Open, Vol 7, Iss 2 (2021)
Objectives To report the efficacy, safety and patient-reported outcome measures (PROs) of tofacitinib modified-release 11 mg once daily plus methotrexate in patients with rheumatoid arthritis (RA) from the open-label phase of Oral Rheumatoid Arthriti
Externí odkaz:
https://doaj.org/article/b9866211020a40c7b198924289c15f38
Publikováno v:
JCR: Journal of Clinical Rheumatology. 29:183-189
Autor:
Inmaculada de la Torre, Masayoshi Harigai, Joel M Kremer, Edward C Keystone, Maher Issa, Christina Dickson, Josh Rancourt, Thomas Melby, Yoshitaka Isaka, Anabela Cardoso, Chadi Saifan
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective To characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.Methods Data were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extensio
Externí odkaz:
https://doaj.org/article/a4233ce845114923aee5548ee591ccb3
Autor:
Bindee Kuriya, Shadi Akhtari, Mohammad Movahedi, Jacob A. Udell, Patrick R. Lawler, Michael E. Farkouh, Edward C. Keystone, Kate Hanneman, Elsie Nguyen, Paula J. Harvey, Lihi Eder
Publikováno v:
Canadian Journal of Cardiology. 38:1244-1252
Patients with inflammatory arthritis (IA) are at high risk for atherosclerotic cardiovascular disease (ASCVD), yet management of dyslipidemia is infrequently prioritized. We applied Canadian dyslipidemia guidelines to determine how many patients with
Publikováno v:
The Journal of Rheumatology. 49:447-453
ObjectiveTofacitinib (TOF) is an oral, small-molecule drug used for rheumatoid arthritis (RA) treatment and is one of several alternative treatments to tumor necrosis factor inhibitors (TNFi). We evaluated physician- and patient-reported effectivenes